Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer
| 対象疾患 | Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma |
|---|---|
| 相 | 第2相 |
| スポンサー | HonorHealth Research Institute |
| ステータス | 完了 |
| 参加者数 | 19 名 |
| 介入（薬剤） | Paclitaxel protein bound, Gemcitabine, Cisplatin, Hydroxychloroquine |
| 開始日 | 2020年12月1日 |
| 完了日 | 2024年2月21日 |
| 結果公開日 | 2026年7月21日 |
概要
To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.
CA 19-9 Normalization
| Treatment | 9.1 Percentage of participants |
|---|---|
| Treatment | 18.2 Percentage of participants |
| Treatment | 72.7 Percentage of participants |
| Treatment | 36.4 Percentage of participants |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroqu — Massachusetts General Hospital
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tum — National Cancer Institute (NCI)
- XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer — XBiotech, Inc.
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanc — National Cancer Institute (NCI)
- Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to t — National Cancer Institute (NCI)
- Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poo — ECOG-ACRIN Cancer Research Group